Asem Alageel

Asem Alageel

Auto-generated profile, based on publicly available information

Asem Alageel

Psychiatry Department, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
AAAsem A. Alageel
Asem A. Alageel
RARayyan A. Alyahya
Rayyan A. Alyahya
YBYasser A. Bahatheq
Yasser A. Bahatheq
NANorah A. Alzunaydi
Norah A. Alzunaydi
RARaed A. Alghamdi
Raed A. Alghamdi
MIMichelle Iacobucci
Michelle Iacobucci
Background: Smartphone addiction, as with other behavioral addictions, is associated with social, physical, and mental health issues. In this article, we investigated the prevalence of smartphone addiction among postgraduate students and evaluated its correlation with social demographics, depression, attention-deficit/hyperactivity disorder (ADHD), and nicotine dependence. Objectives: The objective of this study was to investigate the prevalence of smartphone addiction among Middle Eastern postgraduate students, determine the factors associated with smartphone addiction, and estimate the incidence rate of major depressive disorder (MDD), ADHD, insomnia, and nicotine addiction among postgraduate students with smartphone addiction. Methods: As part of a cross-sectional online survey, participants were given a self-questionnaire divided into six sections: Socio-demographics, Smartphone Addiction Scale (SAS), Patient Health Questionnaire (PHQ9) for Depression, Athens Insomnia Scale (AIS), the Fagerström Test for Cigarette Dependence Questionnaire (FTCd), and the adult ADHD Self-Report Scale (ASRS-v1.1). Results: Of the 506 patients, 51.0% of the participants demonstrated smartphone addiction. A significant association was also observed between extensive smartphone use and MDD (P = 0.001). Of the smokers in this study, 41.5% were addicted to smartphones (P = 0.039). Smartphone addicts had approximately two times the chance of having insomnia (OR = 2.113) (P = 0.013). In addition, they showcased more ADHD symptoms (OR = 2.712) (P < 0.001). Conclusions: We found a positive association among insomnia, depression, adult ADHD, and smartphone addiction, which confirms the findings reported in the previous studies. Therefore, we encourage the scientific community to further study the impacts of smartphone addiction on the mental health of postgraduate students.

31 October 2017 in Expert Opinion on Drug Safety
Verified
Journal Article
Closed access
CRCarola Rong
Carola Rong
NCNicole E. Carmona
Nicole E. Carmona
YLYena L. Lee
Yena L. Lee
RRRenee-Marie Ragguett
Renee-Marie Ragguett
ZPZihang Pan
Zihang Pan
RMRoger McIntyre
Roger McIntyre
Introduction: To determine, via narrative, non-systematic review of pre-clinical and clinical studies, whether the effect of cannabis on hepatic biotransformation pathways would be predicted to result in clinically significant drug-drug interactions (DDIs) with commonly prescribed psychotropic agents. Areas covered: A non-systematic literature search was conducted using the following databases: PubMed, PsycInfo, and Scopus from inception to January 2017. The search term cannabis was cross-referenced with the terms drug interactions, cytochrome, cannabinoids, cannabidiol, and medical marijuana. Pharmacological, molecular, and physiologic studies evaluating the pharmacokinetics of Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), both in vitro and in vivo, were included. Bibliographies were also manually searched for additional citations that were relevant to the overarching aim of this paper. Expert opinion: Δ9-Tetrahydrocannabinol and CBD are substrates and inhibitors of cytochrome P450 enzymatic pathways relevant to the biotransformation of commonly prescribed psychotropic agents. The high frequency and increasing use of cannabis invites the need for healthcare providers to familiarize themselves with potential DDIs in persons receiving select psychotropic agents, and additionally consuming medical marijuana and/or recreational marijuana.

1 January 2021 in European Journal of Psychotraumatology
Verified
Journal Article
Open access
NBNasser F BinDhim
Nasser F BinDhim
Nora AlthumiriNora Althumiri
Nora Althumiri
MBMada H. Basyouni
Mada H. Basyouni
AAAsem A. Alageel
Asem A. Alageel
SASuliman Alghnam
Suliman Alghnam
YAYasser Ad-Dab’bAgh
Yasser Ad-Dab’bAgh
Background: The impact of the COVID-19 pandemic on populations’ mental health has started to emerge. Objectives: To describe the mental health trends of the risk of major depressive disorder (MDD) and generalized anxiety disorder (GAD) between May and August 2020. It also compares the results with pre-COVID-19 results and identifies risk factors associated with increased likelihood of being at risk of MDD and GAD. Method: This study utilizes repeated cross-sectional design, at national-level coverage of mental health screenings via computer-assisted phone interviews conducted in four waves monthly (between May and August 2020). Arabic-speaking adults from Saudi Arabia were recruited via a random phone list. The questionnaire includes the Arabic version of the Patient Health Questionnaire (PHQ-9) and the General Anxiety Disorder-7 (GAD-7). Pre-COVID-19 comparison was done using the PHQ-2 score to allow for comparison with a previous and similar national study conducted in 2018. Results: Across the four waves, 16,513 participants completed the interviews, with an overall response rate of 81.3%. The weighted national prevalence of people at risk of MDD was 14.9% overall, and 13.8%, 13.6%, 16.8%, and 15.3% in Waves 1, 2, 3, and 4, respectively. The weighted national prevalence of people at risk of GAD was 11.4%, overall, and 10.9%, 10.7%, 12.4%, and 11.7% in Waves 1, 2, 3, and 4, respectively. The weighted national proportion of individuals who were at risk of MDD and GAD at the same time was 7.4% overall. The risk of MDD on PHQ-2 increased by 71.2%, from 12.5% in 2018 to 21.4% in 2020. Conclusions: The risks of MDD and GAD in this study are relatively high. These results can help decision makers to understand the impact of the COVID-19 pandemic on the population’s mental health and the most-impacted subgroups. • In the first national study of COVID-19 impact on mental health form Saudi Arabia, the risk of depression in Saudi Arabia increased by 71.2% between May and August 2020 compared to 2018.

1 June 2019 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
ASAisha S. Shariq
Aisha S. Shariq
JRJoshua D. Rosenblat
Joshua D. Rosenblat
AAAsem Alageel
Asem Alageel
RMRodrigo B. Mansur
Rodrigo B. Mansur
CRCarola Rong
Carola Rong
RMRoger McIntyre
Roger McIntyre

1 August 2018 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
AAAsem Alageel
Asem Alageel
JTJulia Tomasi
Julia Tomasi
CTClaudia Tersigni
Claudia Tersigni
EBElisa Brietzke
Elisa Brietzke
HZHannah Zuckerman
Hannah Zuckerman
RMRoger McIntyre
Roger McIntyre

1 September 2018 in Harvard Review of Psychiatry
Verified
Journal Article
Closed access
RMRoger S. McIntyre
Roger S. McIntyre
YLYena Lee
Yena Lee
NCNicole E. Carmona
Nicole E. Carmona
MSMehala Subramaniapillai
Mehala Subramaniapillai
DCDanielle S. Cha
Danielle S. Cha
RMRodrigo B. Mansur
Rodrigo B. Mansur
Learning objectives: After participating in this activity, learners should be better able to: • Characterize cognitive dysfunction in patients with major depressive disorder. • Evaluate approaches to treating cognitive dysfunction in patients with major depressive disorder. Cognitive dysfunction is a core psychopathological domain in major depressive disorder (MDD) and is no longer considered to be a pseudo-specific phenomenon. Cognitive dysfunction in MDD is a principal determinant of patient-reported outcomes, which, hitherto, have been insufficiently targeted with existing multimodal treatments for MDD. The neural structures and substructures subserving cognitive function in MDD overlap with, yet are discrete from, those subserving emotion processing and affect regulation. Several modifiable factors influence the presence and extent of cognitive dysfunction in MDD, including clinical features (e.g., episode frequency and illness duration), comorbidity (e.g., obesity and diabetes), and iatrogenic artefact. Screening and measurement tools that comport with the clinical ecosystem are available to detect and measure cognitive function in MDD. Notwithstanding the availability of select antidepressants capable of exerting procognitive effects, most have not been sufficiently studied or rigorously evaluated. Promising pharmacological avenues, as well as psychosocial, behavioral, chronotherapeutic, and complementary alternative approaches, are currently being investigated.